Antiatherosclerotic effects of Artemisia princeps Pampanini cv. Sajabal in LDL receptor deficient mice.
Antiatherosclerotic effects of ethanolic extracts of Artemisia princeps Pampanini cv. Sajabal (ESJ) were investigated in low-density lipoprotein receptor deficient (LDLR(-/-)) mice. The Western diet-induced high levels of total cholesterol and triglyceride were similar in the ESJ and control groups. However, circulating oxidized LDL was significantly decreased in the ESJ group (p < 0.05). ESJ also markedly decreased aortic expression levels of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 beta (IL-1 beta), and reduced the aortic lesion formation and macrophage accumulation by 36.7% (p < 0.05) and 43% (p < 0.01) in the control group, respectively. Additionally, ESJ inhibited atherogenic properties with cytokine-induced surface expression of cell adhesion molecules, chemokines, and monocyte adhesion to the human umbilical vein endothelial cells (HUVECs), and simultaneously suppressed nuclear factor-kappaB (NF-kappaB) activation. These results suggest that ethanolic extracts of Artemisia princeps Pampanini cv. Sajabal contributes to the antiatherosclerotic and anti-inflammatory activities in LDLR(-/-) mice.
Han
Jong-Min
JM
National Research Laboratory of Lipid Metabolism & Atherosclerosis, KRIBB, Daejeon 305-806, Korea.
Kim
Min-Jung
MJ
Baek
Seung-Hwa
SH
An
Sojin
S
Jin
Yue-Yan
YY
Chung
Hae-Gon
HG
Baek
Nam-In
NI
Choi
Myung-Sook
MS
Lee
Kyung-Tae
KT
Jeong
Tae-Sook
TS
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001011:Aorta / Q000737:chemistry / Q000473:pathology; D019306:Artemisia / Q000737:chemistry*; D050197:Atherosclerosis / Q000473:pathology / Q000517:prevention & control*; D002448:Cell Adhesion; D002478:Cells, Cultured; D002784:Cholesterol / Q000097:blood; D004036:Diet, Atherogenic; D042783:Endothelial Cells / Q000187:drug effects / Q000502:physiology; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis; D053583:Interleukin-1beta / Q000032:analysis; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010936:Plant Extracts / Q000008:administration & dosage*; D011973:Receptors, LDL / Q000172:deficiency*; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000494:pharmacology; D014471:Umbilical Veins; D019010:Vascular Cell Adhesion Molecule-1 / Q000032:analysis
D000893:Anti-Inflammatory Agents; D053583:Interleukin-1beta; D008077:Lipoproteins, LDL; D010936:Plant Extracts; D011973:Receptors, LDL; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D019010:Vascular Cell Adhesion Molecule-1; C099252:oxidized low density lipoprotein; D018799:Intercellular Adhesion Molecule-1; D002784:Cholesterol